Stockholm, Sweden, September 16, 2024 — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer...
Read moreMature results from Medivir’s phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced...
Read moreStockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...
Read more“Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer” April –...
Read moreStockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...
Read moreStockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during...
Read moreNew results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular...
Read moreStockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...
Read moreIn light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 7 May 2024...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...
Read moreMedivir Aktiebolag (publ) held its annual general meeting today on 7 May 2024. The annual general meeting was held by physical...
Read more